This cohort represents the first set of metastatic cancer patients whose tumors were submitted for clinical genomic sequencing with MSK-IMPACT. The team — led by pathology researchers Ahmet Zehir, PhD, and Ryma Benayed, PhD — published their research in Nature Medicine on May 8.
The study focuses on how this genetic information guided clinical decisions for the participating patients. The team found 11 percent of patients were able to participate in clinical trials of treatments that targeted the genetic alterations identified through MSK-IMPACT.
The MSK-IMPACT data will be shared with the scientific community through a database called cBioPortal.
More articles on population health:
US, Canadian health agencies unveil data challenge
IBM Research releases data model to track spread of Ebola virus
Life expectancy differs up to 20 years between counties, study shows
